In this issue:
First-line talazoparib with enzalutamide in HRR-deficient mCRPC
Actinium-225-PSMA radioligand therapy of mCRPC
Olaparib for mCRPC with alterations in BRCA1 and/or BRCA2
Short- or long-term ADT plus EBRT for high-risk localised prostate cancer
Sociodemographic factors and lethal prostate cancer diagnosis
Stimulated Raman histology interpretation by artificial intelligence
Long-term survival estimates after radical prostatectomy
Addition of cribriform and intraductal carcinoma to CAPRA and NCCN tools
Germline APC I1307K variant and treatment-emergent neuroendocrine prostate cancer
BMI, HbA1c and OS with abirateroneor enzalutamide for mCRPC
Please login below to download this issue (PDF)